NEW YORK (GenomeWeb) – Gen9 has signed a deal to supply synthetic DNA to renewable products firm Amyris, the companies announced today.
Under the terms of the agreement, Gen9 will provide Amyris with multiple megabases of synthetic DNA content for use in its microbial engineering pipeline. Additional terms were not disclosed.
"A fast, reliable source of high-quality synthetic DNA constructs is an essential component of our microbial engineering platform for the production of high-value molecules," Joel Cherry, president of R&D at Amyris, said in a statement. "With the DNA synthesis throughput and economics that Gen9 offers, we are able to engineer and test new strains more cost effectively, using them to rapidly identify the highest-performing microbes and allowing us to bring sustainable products to market more quickly."
The deal comes just about two months after Gen9 launched an access program for its low-cost DNA synthesis services. It also follows a supply arrangement Gen9 signed with chemical manufacturer Arzeda in April and a technology-access partnership with SynbiCite in February.